BDTXライブシグナル | Getagraph.comで利益を最大化

買う 107872 min ago

@ $4.67

発行日: 15 2月 2024 @ 03:53

リターン: 20.34%

前回のシグナル: 2月 14 - 05:50

前回のシグナル: 売る

リターン: 11.73 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors...

Stats
本日の出来高	453 722
平均出来高	630 422
時価総額	295.22M
EPS	$0 ( 2024-03-14 )
次の収益日	( $-0.440 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.99
ATR14	$0.0140 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Campbell Shannon	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Raman Prakash	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Campbell Shannon	Buy	0
2024-04-10	Raman Prakash	Buy	0
2024-03-15	Behbahani Ali	Buy	3 166	Common Stock

INSIDER POWER
98.88
Last 97 transactions
Buy: 11 965 700 \| Sell: 275 000

ボリューム相関

長: -0.12 (neutral)

短: 0.91 (very strong)

Signal:(23.615) Expect same movement, but be aware

Black Diamond 相関

10 最も正の相関
SVAC	0.972
RMRM	0.952
TLGT	0.926
ACST	0.919
PXLW	0.916
FEYE	0.898
BLZE	0.877
IMAB	0.877
VVOS	0.877
TMTS	0.875

10 最も負の相関
AMRB	-0.962
NETE	-0.958
MMAC	-0.951
GOODM	-0.903
GLADL	-0.898
SRAC	-0.881
QELL	-0.878
ROCR	-0.874
LWAC	-0.872
RAVN	-0.864

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Black Diamond 相関 - 通貨/商品

0.84
( strong )

0.86
( strong )

0.00
( neutral )

0.75
( moderate )

-0.40
( neutral )

-0.61
( weak negative )

Black Diamond 財務諸表

Annual	2023
収益:	$0
総利益:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2023
収益:	$0
総利益:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2022
収益:	$0
総利益:	$-3.24M (0.00 %)
EPS:	$-2.33

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00347

Financial Reports:

No articles found.

Black Diamond

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.